Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus
Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus
The purpose of this study is to determine whether treatment with
 Daclatasvir/Asunaprevir/BMS-791325, with or without ribavirin, for 8, 6, or 4 weeks is
 feasible for the treatment of genotype 1a chronic hepatitis C in patients without cirrhosis.
Inclusion Criteria:

 -  Subjects chronically infected with HCV genotype 1a

 -  HCV RNA ≥ 10,000 IU/mL at screening

 -  Treatment-naïve subjects with no previous exposure to an interferon formulation (ie,
 IFNα, pegIFNα), ribavirin (RBV), or HCV direct acting antiviral (DAA; protease,
 polymerase inhibitor, etc.)

 Exclusion Criteria:

 -  Evidence of cirrhosis

 -  Liver or any other organ transplant

 -  Current or known history of cancer within 5 years prior to enrollment

 -  Documented or suspected hepatocellular carcinoma (HCC)

 -  Not eligible for sofosbuvir + pegylated interferon + ribavirin therapy